Von Willebrand Factor, recombinant (Vonvendi)

OFFICE ADMINISTRATION

FDA Approved Indications:
  • Indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease
Patients must meet the following criteria for the indications above:
  • Confirmed diagnosis of von Willebrand disease requiring on-demand treatment to control bleeding episodes, AND
  • Patient is at least 18 years old, AND
  • Patient does not have known hypersensitivity to mouse or hamster proteins
Dosing:
  • For each bleeding episode, administer the first dose of Vonvendi with an approved recombinant (non-von Willebrand factor containing) factor VIII [Antihemophilic factor (Recombinant)] if factor VIII baseline levels are below 40% or are unknown.
  • Initial dose of Vonvedi is 40-80 IU per kg.  Adjust dosage based on the extent and location of bleeding
  • If recombinant factor VIII is required, give recombinant factor VIII within 10 minutes of completing Vonvendi infusion at a ration of 1:3:1
  • Administer Vonvendi within 3 hours after reconstitution
Approval:
  • One year